Biodexa Pharmaceuticals plc income statement

In fiscal 2023, Biodexa Pharmaceuticals plc reported revenue of $473,962, down 45.2% on the year before, operating income of −$10.0m (a -2103.4% margin) and net income of −$8.8m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Biodexa Pharmaceuticals plc: income statement, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023
Revenue	2	2	1	3	1	0	1	1	0
Cost of revenue	0	1	1	—	—	—	—	—	—
Gross profit	2	8	9	—	—	—	—	—	—
Research and development	13	10	11	13	10	8	6	6	5
General and administrative	8	4	5	6	5	6	4	6	5
Operating income	−20	−13	−17	−16	−14	−30	−10	−11	−10
Interest expense	—	—	—	0	0	0	0	0	0
Income before tax	−17	−11	−17	−17	−14	−30	−8	−11	−9
Income tax	−2	−3	−2	−3	2	−2	−1	−1	−1
Net income	−15	−27	−21	−20	−13	−28	−8	−9	−9
Diluted EPS	—	—	—	—	—	—	—	−$191753.91	—
Diluted shares (average)	—	—	—	—	—	—	—	—	—
EBITDA	−20	−13	−17	−16	—	—	—	—	—

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Biodexa Pharmaceuticals plc's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biodexa Pharmaceuticals plc.